Hyphens Pharma International Limited (SGX:1J5)

Singapore flag Singapore · Delayed Price · Currency is SGD
0.3550
-0.0200 (-5.33%)
At close: Sep 26, 2025
22.41%
Market Cap 109.65M
Revenue (ttm) 185.32M
Net Income (ttm) 6.46M
Shares Out 308.87M
EPS (ttm) 0.02
PE Ratio 17.35
Forward PE 9.83
Dividend 0.02 (4.23%)
Ex-Dividend Date May 7, 2025
Volume 201,400
Average Volume 333,685
Open 0.3700
Previous Close 0.3750
Day's Range 0.3550 - 0.3700
52-Week Range 0.2600 - 0.3950
Beta -0.01
RSI 49.93
Earnings Date Nov 7, 2025

About SGXC:1J5

Hyphens Pharma International Limited, together with its subsidiaries, operates as a specialty pharmaceutical and consumer healthcare company primarily in Singapore, Vietnam, Malaysia, and internationally. It operates through Specialty pharma principals; Proprietary brands; and Medical hypermart and digital segments. The Specialty Pharma Principals segment markets and sells specialty pharmaceutical products, including contrast media products, Stérimar nasal sprays, Bausch+Lomb eye drops, Vivomixx, Fenosup Lidose, and Piascledine products through... [Read more]

Industry Pharmaceutical Preparations
Founded 1998
Employees 474
Stock Exchange Singapore Exchange - Catalist
Ticker Symbol 1J5
Full Company Profile

Financial Performance

In 2024, SGXC:1J5's revenue was 195.42 million, an increase of 14.55% compared to the previous year's 170.60 million. Earnings were 10.19 million, an increase of 18.98%.

Financial Statements

News

There is no news available yet.